Latest News
Vaxcyte, Inc.
- Vaxcyte’s 31-strain pneumococcal conjugate vaccine passes phase 3 test
- Why is Vaxcyte stock sliding today? By Investing.com
- Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
- Vaxcyte Announces Pricing of Concurrent Public Offerings of
- Vaxcyte shares surge as pneumococcal vaccine meets main trial goals
- Vaxcyte's 31-valent pneumococcal vaccine hits goals of first late-stage study
- Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
- Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
- Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
- Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
- Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
- Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Headlines from the last 30 days, linking to the original publishers. See all market news →